| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2849738 | American Heart Journal | 2009 | 8 Pages |
Abstract
RE-LY is the largest AF stroke prevention trial yet undertaken. It is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of dabigatran, which may allow tailoring of dosing to individual patient needs. The worldwide site distribution and broad range of stroke risk further increase the general applicability of the trial. Results are expected in 2009.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Michael D. MBChB, DPhil, Stuart MD, Amit MD, Paul A. PhD, Jeanne MD, Susan PhD, Jonas MD, PhD, Ellison Themeles, Lars MD, PhD, Salim FRCP(c), FRSC, DPhil,